EU/3/11/918

About

Please note that this product was withdrawn from the Community register of designated orphan medicinal products in April 2013 on request of the sponsor.

On 27 October 2011, orphan designation (EU/3/11/918) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for brivanib alaninate for the treatment of hepatocellular carcinoma.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Brivanib alaninate
Disease / condition
Treatment of hepatocellular carcinoma
Date of first decision
27/10/2011
Outcome
Withdrawn
EU designation number
EU/3/11/918

Review of designation

Please note that this product was withdrawn from the Community register of designated orphan medicinal products in April 2013 on request of the sponsor, before a marketing authorisation had been granted.

Sponsor's contact details

Bristol-Myers Squibb Pharma EEIG
Uxbridge Business Park
Sanderson Road
Uxbridge
UB8 1DH
United Kingdom
Tel. +44 (0)1895 523517
Fax +44 (0)20 8754 3576
E-mail: medical.information@bms.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating